title: Intravenous cidofovir for resistant cutaneous warts in a patient with psoriasis treated with monoclonal antibodies.
abstract: Human papilloma virus is a common and often distressing cutaneous disease. It can be therapeutically challenging, especially in immunocompromised patients. We report a case of recalcitrant cutaneous warts that resolved with intravenous cidofovir treatment. The patient was immunocompromised secondary to monoclonal antibody therapy for psoriasis.
authors.affiliation: Department of Dermatology, South Infirmary-Victoria University Hospital, Cork, Co. Cork, Ireland.
authors.forename: M A
authors.initials: MA
authors.lastname: McAleer
authors.forename: J
authors.initials: J
authors.lastname: Bourke
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage*; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D016867:Immunocompromised Host; D007262:Infusions, Intravenous; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage*; D011565:Psoriasis / Q000628:therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use; D014860:Warts / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D063065:Organophosphonates; D014409:Tumor Necrosis Factor-alpha; D003596:Cytosine; D000068879:Adalimumab; D000077404:Cidofovir; C472181:efalizumab